Lexicon Pharma Q3 net loss narrows as R&D costs drops

Reuters11-06

Lexicon Pharma Q3 net loss narrows as R&D costs drops

Overview

Lexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenue
Net loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024
R&D expenses decreased to $18.8 mln due to lower external research costs

Outlook

Lexicon expects 2026 to be pivotal for strategic initiatives
FDA feedback on Zynquista resubmission expected in Q4 2025
Novo Nordisk preparing IND submission for LX9851, triggering potential milestone payments

Result Drivers

LICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo Nordisk
EXPENSE REDUCTION - Decrease in R&D and SG&A expenses due to strategic repositioning and reduced marketing efforts

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Product Revenue		$1.01 mln
Q3 EPS		-$0.04
Q3 Net Income		-$12.77 mln
Q3 Basic EPS		-$0.04
Q3 Operating Expenses		$26.37 mln
Q3 Operating Income		-$12.19 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.90, about 27.4% above its November 5 closing price of $1.38

Press Release: ID:nGNX8DQckG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581024060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581024060","market":"fut","top_or_hot":-1,"title":"Lexicon Pharma Q3 net loss narrows as R&D costs drops","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Lexicon Pharma Q3 net loss narrows as R&amp;D costs drops</title></head><body><p><span>Overview</span></p><ul><li><p>Lexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenue</p></li><li><p>Net loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024</p></li><li><p>R&amp;D expenses decreased to $18.8 mln due to lower external research costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lexicon expects 2026 to be pivotal for strategic initiatives</p></li><li><p>FDA feedback on Zynquista resubmission expected in Q4 2025</p></li><li><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> preparing IND submission for LX9851, triggering potential milestone payments</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo Nordisk</p></li><li><p>EXPENSE REDUCTION - Decrease in R&amp;D and SG&amp;A expenses due to strategic repositioning and reduced marketing efforts</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$1.01 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.77 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$26.37 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$12.19 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.90, about 27.4% above its November 5 closing price of $1.38</p></li></ul><p>Press Release: <span>ID:nGNX8DQckG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Pharma Q3 net loss narrows as R&D costs drops</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Pharma Q3 net loss narrows as R&D costs drops\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Lexicon Pharma Q3 net loss narrows as R&amp;D costs drops</title></head><body><p><span>Overview</span></p><ul><li><p>Lexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenue</p></li><li><p>Net loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024</p></li><li><p>R&amp;D expenses decreased to $18.8 mln due to lower external research costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lexicon expects 2026 to be pivotal for strategic initiatives</p></li><li><p>FDA feedback on Zynquista resubmission expected in Q4 2025</p></li><li><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> preparing IND submission for LX9851, triggering potential milestone payments</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo Nordisk</p></li><li><p>EXPENSE REDUCTION - Decrease in R&amp;D and SG&amp;A expenses due to strategic repositioning and reduced marketing efforts</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$1.01 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.77 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$26.37 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$12.19 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.90, about 27.4% above its November 5 closing price of $1.38</p></li></ul><p>Press Release: <span>ID:nGNX8DQckG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0O8:1","article_id":"2581024060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581024060","pubTimestamp":1762432771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexicon Pharma Q3 net loss narrows as R&D costs dropsOverviewLexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenueNet loss for Q3 2025 was $12.8 mln, significantly lower th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LXRX":"莱斯康制药"},"translate_title":"随着研发成本下降，Lexicon Pharma第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":0.9},"content_text":"Lexicon Pharma Q3 net loss narrows as R&D costs dropsOverviewLexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenueNet loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024R&D expenses decreased to $18.8 mln due to lower external research costsOutlookLexicon expects 2026 to be pivotal for strategic initiativesFDA feedback on Zynquista resubmission expected in Q4 2025Novo Nordisk preparing IND submission for LX9851, triggering potential milestone paymentsResult DriversLICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo NordiskEXPENSE REDUCTION - Decrease in R&D and SG&A expenses due to strategic repositioning and reduced marketing effortsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Product Revenue$1.01 mlnQ3 EPS-$0.04Q3 Net Income-$12.77 mlnQ3 Basic EPS-$0.04Q3 Operating Expenses$26.37 mlnQ3 Operating Income-$12.19 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.90, about 27.4% above its November 5 closing price of $1.38Press Release: ID:nGNX8DQckGFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581024060","isCrawlerRequest":true}